Q1: The ascites-specific adjuvant is effective, but the injection resistance is high and the needle容易脱针. How to deal with this?
Our ascites adjuvant has a different composition from the conventional adjuvants. It is relatively more viscous and can be used with a syringe without a rubber stopper or a release needle. Rubber-free syringe, anti-disengagement syringe
Q2: Does injecting hybridoma cells beyond a few days have any impact?
The instruction manual states that 12 to 18 days after sensitization, hybridoma cells should be injected. Generally, it is fine within 25 days after sensitization. We have done it for up to 30 days, which is still okay. However, 12 to 18 days is the best. If it exceeds 25 days, it is generally not recommended to do it again. You can try your luck and directly inject the cells without adding adjuvants.
Q3: Low or no ascites production
(1) Incorrect sensitization, incorrect use of sensitizers, or a significant time difference between sensitization and hybridoma inoculation, usually 7 to 14 days, depending on the abdominal condition of the mouse. (2) The hybridoma cells or sensitizers were inoculated at incorrect locations, not reaching the abdominal cavity but subcutaneous. (3) The number of hybridoma cells inoculated is too small, too many or the cell condition is poor. Generally, it is advisable not to have around 500,000 cells. (4) It is recommended to use female mice or those that have given birth to prepare ascites.
Q4: Low ascites titer
(1) The hybridoma used to prepare ascites is extremely unstable. It loses its antibody secretion capacity before being injected into mice or within the abdominal cavity. (2) The wrong sensitizer was used when sensitizing the mice; (3) The number of hybridoma cells inoculated is too small, or the cell condition is poor; (4) Due to incorrect injection methods and sites, solid tumors were formed.
Q5: Formation of solid tumors
Two situations may lead to solid tumors: (1) The number of hybridoma cells is too large, or the "toxicity" of hybridoma cells is relatively strong, and the number of hybridomas needs to be appropriately reduced; (2) The hybridoma cells have been contaminated by microorganisms, and the injected hybridoma cells are impure. In this case, the hybridoma cells need to be taken and re-inoculated with 5x antibiotics, and then ascites should be prepared.
Q6: Precautions for Use
Precautions for Use
Q7: 1. The ascites-specific adjuvant is effective, but the injection resistance is high and the needle容易脱针. How to deal with this?
Our ascites adjuvant has a different composition from the conventional adjuvants. It is relatively more viscous and can be used with a syringe without a rubber stopper or a release needle.
Q8: 2. Low or no ascites production
(1) Incorrect sensitization, incorrect use of sensitizers, or a significant time difference between sensitization and hybridoma inoculation, usually 7 to 14 days, depending on the abdominal condition of the mouse;
(2) The hybridoma cells or sensitizers were inoculated at incorrect locations, not reaching the abdominal cavity but subcutaneous.
(3) The number of hybridoma cells inoculated is too small, too many or the cell condition is poor. Generally, it is advisable not to have around 500,000 cells.
(4) It is recommended to use female mice or those that have given birth to prepare ascites.
Q9: 3. Low ascites titer
(1) The hybridoma used to prepare ascites is extremely unstable. It loses its antibody secretion capacity before being injected into mice or once injected into the abdominal cavity.
(2) The wrong sensitizer was used when sensitizing the mice;
(3) The number of hybridoma cells inoculated is too small, or the cell condition is poor;
(4) Due to incorrect injection methods and sites, solid tumors were formed.
Q10: 4. Formation of solid tumors
Two situations may lead to solid tumors:
(1) The number of hybridoma cells is too large, or the hybridoma cells ";" "Toxicity" It is relatively strong and the number of hybridomas needs to be appropriately reduced.
(2) The hybridoma cells have been contaminated by microorganisms, and the injected hybridoma cells are impure. In this case, the hybridoma cells need to be taken and re-inoculated with 5x antibiotics, and then ascites should be prepared.
Q11: 5. Usage precautions
The intraperitoneal injection site was located in the lower abdomen on the left or right side of the mouse, avoiding the liver and the lower and middle abdominal bladder, and penetrated the peritoneum along the Angle of the leg. When the 1ml syringe needle enters about one-third, there is a feeling of being pierced through.
Q12: Although the ascites adjuvant has a good effect, it has high injection resistance and is prone to needle detachment. How to deal with it
Although the ascites adjuvant has a good effect, it has high injection resistance and is prone to needle detachment. How to deal with it
Q13: Is there any effect after injecting hybridoma cells for several days
Is there any effect after injecting hybridoma cells for several days
Q14: Little ascites or no ascites
Little ascites or no ascites
Q15: The potency of ascites is low
The potency of ascites is low
Q16: Form a solid tumor
Form a solid tumor
Q17: Usage precautions.
The intraperitoneal injection site was located in the lower abdomen on the left or right side of the mouse, avoiding the liver and the lower and middle abdominal bladder, and penetrated the peritoneum along the Angle of the leg. When the 1ml syringe needle enters about one-third, there is a feeling of being pierced through.
Q18: What is the material of the needle in the adjuvant emulsifier? Worried about residues in the reagent from the vibrating needle.
No residues have been detected in stainless steel and copper for the time being, nor have any feedback been received regarding any residues